Mar 2
|
Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?
|
Feb 27
|
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
|
Feb 20
|
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
|
Feb 18
|
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
|
Feb 14
|
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
|
Feb 13
|
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
|
Feb 10
|
With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing
|
Jan 22
|
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?
|
Jan 21
|
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
|
Jan 21
|
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
|
Oct 10
|
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years
|
Oct 9
|
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
|
Jul 30
|
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
|
Jul 25
|
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
Jul 23
|
Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
|
Jul 17
|
Evolus to Report Second Quarter Financial Results on July 31, 2024
|
Jun 24
|
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
|
Jun 19
|
Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
|
May 15
|
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
|
May 10
|
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
|